northwest biotherapeutics, inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. the company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. the company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. the company’s platform technology, dcvax®, uses a patient’s own dendritic cells, the starter engine of the immune system. the dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘
Company profile
Ticker
NWBO
Exchange
Website
CEO
Linda Powers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Northwest Biotherapeutics Limited • Aracaris Capital, Ltd. • NW Bio Gmbh • Northwest Biotherapeutics B.V. • Flaskworks LLC ...
IRS number
943306718
NWBO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Entry into a Material Definitive Agreement
8 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm |
Cash burn (monthly) | (no burn) | 277.33 k | 4.61 mm | 4.88 mm | 4.64 mm | 3.79 mm |
Cash used (since last report) | n/a | 1.91 mm | 31.70 mm | 33.55 mm | 31.91 mm | 26.09 mm |
Cash remaining | n/a | 4.19 mm | -25.60 mm | -27.46 mm | -25.81 mm | -20.00 mm |
Runway (months of cash) | n/a | 15.1 | -5.6 | -5.6 | -5.6 | -5.3 |
Institutional ownership, Q3 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 99.00 k |
Total shares | 109.72 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Opus Capital | 60.15 k | $55.00 k |
Lee Danner & Bass | 20.00 k | $18.00 k |
AlphaMark Advisors | 14.01 k | $13.00 k |
Advisors Management | 10.27 k | $9.00 k |
Bartlett & Co. | 4.29 k | $4.00 k |
Coston, McIsaac & Partners | 1.00 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Nov 23 | Navid Malik | Common Stock | Sell | Acquire S | No | No | 0.819 | 295,000 | 241.60 k | 0 |
17 Nov 23 | Navid Malik | Common Stock | Sell | Acquire S | No | No | 0.823 | 150,000 | 123.45 k | 295,000 |
16 Nov 23 | Navid Malik | Common Stock | Sell | Acquire S | No | No | 0.835 | 125,000 | 104.38 k | 445,000 |
4 Apr 23 | Boynton Alton L | STOCK OPTIONS COMMON STOCK PAR VALUE $0.001 | Gift | Dispose G | No | No | 0.35 | 6,794,191 | 2.38 mm | 2,967,065 |
3 Apr 23 | Bosch Marnix L | Common Stock | Grant | Acquire A | No | No | 0.25 | 119,355 | 29.84 k | 119,355 |
6 Dec 22 | Boynton Alton L | COMMON STOCK OPTIONS COMMON STOCK PAR VALUE $0.001 | Gift | Dispose G | No | No | 0.35 | 4,500,000 | 1.58 mm | 9,761,256 |
6 Dec 22 | Boynton Alton L | COMMON STOCK OPTIONS COMMON STOCK PAR VALUE $0.001 | Gift | Dispose G | No | No | 0.35 | 4,500,000 | 1.58 mm | 9,761,256 |
1 Dec 22 | Jerry J Jasinowski | Series C Convertible Preferred Stock | Grant | Acquire A | No | No | 21.25 | 28,235 | 599.99 k | 28,235 |
27 Jul 22 | Boynton Alton L | COMMON STOCK OPTIONS COMMON STOCK PAR VALUE $0.001 | Gift | Dispose G | No | No | 0.35 | 3,000,000 | 1.05 mm | 9,761,256 |
26 May 22 | Boynton Alton L | COMMON STOCK OPTIONS COMMON STOCK PAR VALUE $0.001 | Gift | Dispose G | No | No | 0.23 | 4,900,000 | 1.13 mm | 9,761,256 |
Press releases
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
21 Mar 24
12 OTC Stocks to Watch: Clean Vision Corporation (OTCQB: CLNV), NaturalShrimp Inc (OTCQB: SHMP), Northwest Biotherapeutics, Inc. (OTCQB: NWBO), and More
22 Feb 24
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
6 Feb 24